(PharmaNewsWire.Com, February 27, 2018 ) Acute Intermittent Porphyria Market is expected to grow at a CAGR of 5.6 % during the forecast period 2017-2023. Although the prevalence of this disease is considered rare. Porphyria is a disorder that occurs when there is a build-up of the chemicals in the body that produce a substance called porphyrin. Acute intermittent porphyria (AIP) is a genetic metabolic disorder is one of the 8 types of porphyria. It affects the production of heme, the oxygen-binding prosthetic group of hemoglobin. Children have a 50% chance of inheriting any of the 8 different types of porphyria if their parents have the disorder.
Increasing prevalence of rare diseases, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. Moreover, increasing government support for research & development, changing lifestyle, and rapidly developing technology is expected to fuel the market growth during the forecast period. However, high cost of the treatment may slow the market growth during the period 2017-2023.
The Americas dominate the global acute intermittent porphyria market owing to the presence of huge patient population with gastrointestinal problems, neurological issues, high healthcare spending, and increasing government support for research & development.
Europe holds the second largest share of the global acute intermittent porphyria market as result of increasing focus of various government agencies on the treatment of rare diseases such as Acute Intermittent Porphyria. Moreover, the growing public awareness about Acute Intermittent Porphyria likely to boost the Europe market.
Asia Pacific is the fastest growing acute intermittent porphyria market across the globe. Japan holds the major share of the regional market due to availability of advanced technology and huge healthcare spending. Moreover, rapidly developing economy, increasing healthcare expenditure, and the government’s initiatives for research & development projected to drive the market in China and India over the forecasted period.
Some of key the players in the market are Dahaner (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens AG (U.S.), ARKRAY, Inc. (Japan), Sysmex Corporation (Japan), and ACON Laboratories, Inc. (U.S.).
LIST OF TABLES:
Table 1 Acute Intermittent Porphyria Industry Synopsis, 2017-2023
Table 2 Global Acute Intermittent Porphyria Market Estimates And Forecast, 2017-2023, (USD Million)
Table 3 Global Acute Intermittent Porphyria Market By Region, 2017-2023, (USD Million)
Table 4 Global Acute Intermittent Porphyria Market By Diagnosis, 2017-2023, (USD Million)
Table 5 Global Acute Intermittent Porphyria Market By Treatment, 2017-2023, (USD Million)
Table 6 Global Acute Intermittent Porphyria Market By End Users, 2017-2023, (USD Million)
Table 7 North America Acute Intermittent Porphyria Market By Diagnosis, 2017-2023, (USD Million)
Table 8 North America Acute Intermittent Porphyria Market By Treatment, 2017-2023, (USD Million)
Table 9 North America Acute Intermittent Porphyria Market By End Users, 2017-2023, (USD Million)
Table 10 U.S. Acute Intermittent Porphyria Market By Diagnosis, 2017-2023, (USD Million)
Table 11 US Acute Intermittent Porphyria Market By Treatment, 2017-2023, (USD Million)
Table 12 US Acute Intermittent Porphyria Market By End Users, 2017-2023, (USD Million)
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
